45724 VC2 Oncolytic Virotherapy Induces Robust Systemic Anti-Tumor Immunity and Increases Survival in an Immunocompetent B16F10-derived Mouse Melanoma Model

ABSTRACT IMPACT: Our data demonstrate that VC2 oncolytic virotherapy has significant clinical potential. OBJECTIVES/GOALS: Use our novel oncolytic herpes simplex virus type I (HSV-1), VC2, to understand how oncolytic virotherapy affects the immunosuppressive tumor microenvironment as a mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales: Uche, Ifeanyi Kingsley, Fowlkes, Natalie, Vu, Luan, Watanabe, Tatiane, Carossino, Mariano, Nabi, Rafiq, Del Piero, Fabio, Rudd, Jared S., Kousoulas, Konstantin G., Rider, Paul J.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827672/
http://dx.doi.org/10.1017/cts.2021.437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827672/
http://dx.doi.org/10.1017/cts.2021.437

Ejemplares similares